Maze Therapeutics CEO Jason V. Coloma Sells $1.04M of Stock
Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $30.09 to $31.05 a share (average $30.25) in 4 transactions, worth $1.04M in total on Nov 2, 2026. Shares held after the trade: 186,901 (-2.8%).
Maze Therapeutics Csbo Atul Dandekar Sells $241K of Stock
Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $32.07 a share, worth $241K in total on Oct 29, 2026. Shares held after the trade: 32,316 (-18.8%).
Maze Therapeutics CEO Jason V. Coloma Sells $932K of Stock
Jason V. Coloma, CEO, sold 34,501 shares of Maze Therapeutics, Inc. at $27.02 to $27.02 a share (average $27.02) in 2 transactions, worth $932K in total on Oct 1, 2026. Shares held after the trade: 191,447 (-14.3%).
Maze Therapeutics President, R&D & CMO Harold Bernstein Sells $435K of Stock
Harold Bernstein, President, R&D & CMO, sold 16,141 shares of Maze Therapeutics, Inc. at $26.93 a share, worth $435K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).
Maze Therapeutics Csbo Atul Dandekar Sells $203K of Stock
Atul Dandekar, Csbo, sold 7,500 shares of Maze Therapeutics, Inc. at $27.06 a share, worth $203K in total on Sep 29, 2026. Shares held after the trade: 32,316 (-18.8%).